S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (Ad)
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
He Is Giving Away Bitcoin (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
How Biden has already won 2024 (Ad)
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
These are the Top 4 Stocks for Buybacks in 2024
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (Ad)
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
He Is Giving Away Bitcoin (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
How Biden has already won 2024 (Ad)
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
These are the Top 4 Stocks for Buybacks in 2024
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (Ad)
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
He Is Giving Away Bitcoin (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
How Biden has already won 2024 (Ad)
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
These are the Top 4 Stocks for Buybacks in 2024
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (Ad)
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
He Is Giving Away Bitcoin (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
How Biden has already won 2024 (Ad)
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
These are the Top 4 Stocks for Buybacks in 2024
Free Trial
OTCMKTS:GNWSF

StageZero Life Sciences (GNWSF) Stock Price, News & Analysis

→ You’re invited: Biggest crypto event of 2024 (From InvestorPlace) (Ad)
Free GNWSF Stock Alerts
$0.04
0.00 (0.00%)
(As of 04/18/2024 ET)
Compare
Today's Range
$0.04
▼
$0.04
50-Day Range
$0.03
▼
$0.04
52-Week Range
$0.00
▼
$1.27
Volume
N/A
Average Volume
26,719 shs
Market Capitalization
$2.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChartFinancialsHeadlinesSEC Filings
GNWSF stock logo

About StageZero Life Sciences Stock (OTCMKTS:GNWSF)

StageZero Life Sciences Ltd. develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology is Sentinel Principle, which identifies novel biomarkers from whole blood. The company's lead product is ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer. It also offers Aristotle, a multi-cancer panel test for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer; and COVID PCR testing and blood test analysis. StageZero Life Sciences Ltd. is headquartered in Richmond Hill, Canada.

GNWSF Stock Price History

GNWSF Stock News Headlines

April 4, 2024 | theglobeandmail.com
StageZero Life Sciences: Top 10 Undervalued Healthcare Sector Stocks on TSX (SZLS)
March 5, 2024 | msn.com
Life Below Zero Season 9 Streaming: Watch & Stream Online via Disney Plus
April 19, 2024 | InvestorPlace (Ad)
New crypto project uncovers 2,050% in 65 days
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
February 15, 2024 | bizjournals.com
Wu awards $4.7 million to train Bostonians in life sciences industry
February 3, 2024 | msn.com
What Is the Sandwich Generation? Here’s What You Need to Know About This Growing Cohort
November 15, 2023 | finance.yahoo.com
StageZero Life Sciences, Ltd Announces Q3 2023 Financial Results and Operational Update
October 26, 2023 | bizjournals.com
In life sciences, Boston continues to reign supreme
October 5, 2023 | bizjournals.com
New York City life-science market ranks among top 10 in country
April 19, 2024 | InvestorPlace (Ad)
New crypto project uncovers 2,050% in 65 days
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
October 3, 2023 | bizjournals.com
Syneos Health replaces CEO with life sciences veteran Colin Shannon days after $7B deal closes
September 12, 2023 | markets.businessinsider.com
Sustainability, equipment upgrades, and digitalization: big priorities for global pharmaceuticals, life science global study finds
September 11, 2023 | msn.com
Report: Mass. life sciences grew in 'toughest times' in Worcester, Suffolk counties
June 29, 2023 | finance.yahoo.com
Canadian Investment Regulatory Organization Trading Halt - SZLS.WT
June 20, 2023 | finance.yahoo.com
StageZero Life Sciences, Ltd. Announces Temporary Repricing of Warrants Expiring in 2023 and 2024
June 5, 2023 | finance.yahoo.com
StageZero Life Sciences, Ltd. Special and Annual General Meeting Conference Call
May 29, 2023 | msn.com
5 innovators to watch in R.I.’s life sciences industry
May 16, 2023 | msn.com
StageZero Life Sciences Ltd. GAAP EPS of -$0.02, revenue of $0.8M
May 12, 2023 | technews.tmcnet.com
Life Science Instrumentation Market worth $73.9 billion | MarketsandMarkets
April 6, 2023 | bizjournals.com
Demand outstripping construction in L.A.'s life-science real estate market
March 31, 2023 | finance.yahoo.com
StageZero Life Sciences, Ltd Announces Q4 2022 and Year End Financial Results and Operational Update
January 25, 2023 | forbes.com
It's Time For The Life Sciences Industry To Embrace Quality 4.0
January 17, 2023 | nytimes.com
What Happened to All of Science’s Big Breakthroughs?
December 10, 2022 | theglobeandmail.com
StageZero Life Sciences: Bottom 25 Performing Stocks Year-to-Date on TSX (SZLS)
August 18, 2022 | finance.yahoo.com
StageZero Life Sciences Announces Closing of Convertible Debenture Financing
August 17, 2022 | finanznachrichten.de
StageZero Life Sciences Ltd: StageZero Life Sciences, Ltd Announces Q2 2022 Financial Results and Operational Update
August 16, 2022 | seekingalpha.com
StageZero Life Sciences Ltd. (SZLSF) CEO James Howard-Tripp on Q2 2022 Results - Earnings Call Transcript
August 16, 2022 | finance.yahoo.com
StageZero Life Sciences, Ltd Announces Q2 2022 Financial Results and Operational Update
See More Headlines
Receive GNWSF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for StageZero Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Diagnostic Substances
Sub-Industry
N/A
Current Symbol
OTCMKTS:GNWSF
CUSIP
N/A
CIK
1454263
Web
www.stagezerolifesciences.com
Phone
905-209-2030
Fax
N/A
Employees
51
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($0.28)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-6,860,000.00
Net Margins
-200.26%
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-165.13%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.15
Quick Ratio
1.08

Sales & Book Value

Annual Sales
$4.15 million
Price / Sales
0.59
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.02) per share
Price / Book
-1.95

Miscellaneous

Outstanding Shares
62,995,000
Free Float
N/A
Market Cap
$2.46 million
Optionable
Not Optionable
Beta
0.28
13 Stocks Institutional Investors Won't Stop Buying Cover
13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. James R. Howard-Tripp
    Exec. Chairman & CEO
  • Mr. Carl Solomon
    Interim Chief Financial Officer
  • Prof. Choong-Chin Liew
    Co-Founder
  • Mr. Warren Whitehead C.M.A. (Age 69)
    Chief Accountant
  • Mr. David Suria
    Sr. Scientist

Key Competitors

View All Competitors

GNWSF Stock Analysis - Frequently Asked Questions

How have GNWSF shares performed in 2024?

StageZero Life Sciences' stock was trading at $0.0294 on January 1st, 2024. Since then, GNWSF shares have increased by 32.7% and is now trading at $0.0390.
View the best growth stocks for 2024 here.

How do I buy shares of StageZero Life Sciences?

Shares of GNWSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:GNWSF) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Biden’s $374B Giveaway Into This Sector
DTI
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
Paradigm Press
He Is Giving Away Bitcoin
Crypto Swap Profits
The #1 Crypto for 2024
InvestorPlace
Urgent alert: open this for a huge profit potential
Timothy Sykes
How Biden has already won 2024
Porter & Company
Options trading has suddenly become more reliable.
Eagle Publishing